Clinical Roundup: Gene-Edited CAR T Therapies
Feb. 6, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Fate Therapeutics
General information
Main focus: Allogeneic natural killer cell therapies
Company stage: Clinical
Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:FATE)
Location: San Diego, CA, USA
Website: https://fatetherapeutics.com/
Pipeline: https://fatetherapeutics.com/pipeline/
Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta
Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.
